aTyr Pharma/$ATYR
1D1W1MYTD1Y5YMAX
Capital at risk
About aTyr Pharma
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
- Ticker
- $ATYR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 59
- Headquarters
- San Diego, United States
- Website
- atyrpharma.com
aTyr Pharma Metrics
BasicAdvanced
$37M
-
-$0.62
0.53
-
Price and volume
Market cap
$37M
Beta
0.53
52-week high
$1.12
52-week low
$0.37
Average daily volume
726K
Financial strength
Current ratio
5.121
Quick ratio
5.207
Long term debt to equity
0.202
Total debt to equity
0.233
Profitability
EBITDA (TTM)
-63.197
Gross margin (TTM)
-24,682.11%
Net profit margin (TTM)
-32,003.68%
Operating margin (TTM)
-33,609.47%
Management effectiveness
Return on assets (TTM)
-46.58%
Return on equity (TTM)
-98.68%
Valuation
Price to revenue (TTM)
193.972
Price to book
0.76
Price to tangible book (TTM)
0.76
Price to free cash flow (TTM)
-0.672
Free cash flow yield (TTM)
-148.79%
Free cash flow per share (TTM)
-0.56
Growth
Earnings per share change (TTM)
-21.84%
3-year revenue growth (CAGR)
-73.65%
3-year earnings per share growth (CAGR)
-18.86%
10-year earnings per share growth (CAGR)
-33.18%
What the Analysts think about aTyr Pharma
Analyst ratings (Buy, Hold, Sell) for aTyr Pharma stock.
Analyst projections of the future price of aTyr Pharma stock.
aTyr Pharma Financial Performance
Revenues and expenses
aTyr Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.